Extended Data Fig. 1: Analysis of event-free survival in the patients with carcinoma in situ at randomization (with or without papillary tumors) for sasanlimab + BCG-I+M vs BCG-I+M. | Nature Medicine

Extended Data Fig. 1: Analysis of event-free survival in the patients with carcinoma in situ at randomization (with or without papillary tumors) for sasanlimab + BCG-I+M vs BCG-I+M.

From: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Extended Data Fig. 1

For EFS, an event was defined as the first of recurrence of high-grade disease, progression of disease, persistence of CIS (for patients with CIS at randomization), or death due to any cause. Kaplan-Meier estimates of EFS according to treatment arm. The dashed line indicates EFS at 36 months. BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; CIS, carcinoma in situ; EFS, event-free survival.

Back to article page